Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by BridgeBio Pharma, Inc.
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
March 23, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
March 21, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
March 17, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 08, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
March 06, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
March 03, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
February 23, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
February 13, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Participate in February and March Investor Events
February 08, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
January 04, 2023
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
December 22, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Participate in November Investor Events
November 09, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 03, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
October 17, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
October 14, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
October 13, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
October 11, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
October 07, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
July 26, 2022
From
BridgeBio Pharma, Inc.
Via
Globe NewsWire
Tickers
BBIO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.